Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
- Conditions
- Gastroparesis NondiabeticGastroparesisGastroparesis Due to Diabetes Mellitus
- Registration Number
- NCT05980455
- Lead Sponsor
- Enterra Medical, Inc.
- Brief Summary
The purpose of this research study is to evaluate if different Enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.
Participants in this study with existing Enterra® devices will be randomly assigned to one of three programming methods that will be active during sleep. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at study visits.
Participants will be involved in the study for up to six months after treatment assignment.
Programming parameters in the study are within currently approved labeling.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 50
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percent Change in Weekly Vomiting Frequency by GCSI-DD 3 Months, 6 Months Less than a 50% increase in GCSI-DD weekly vomiting frequency from baseline
Scoring Change in Nausea Severity by GCSI-DD 3 Months, 6 Months Less than a 1-point increase in GCSI-DD nausea severity from baseline
- Secondary Outcome Measures
Name Time Method Mean Change from Baseline in PAGI-QoL Scores 3 Months, 6 Months Change in PAGI-QoL from baseline
Mean Change from Baseline in Quality of Sleep Scores 3 Months, 6 Months Change in Quality of Sleep from baseline
Mean Change from Baseline in GCSI-DD Weekly Vomiting Frequency 3 Months, 6 Months Change in GCSI-DD weekly vomiting frequency from baseline
Mean Change from Baseline in GCSI-DD Total Symptom Score 3 Months, 6 Months Change in GCSI-DD Total Symptom Score from baseline
Mean Change from Baseline in GCSI-DD Nausea Severity 3 Months, 6 Months Change in GCSI-DD nausea severity from baseline
Trial Locations
- Locations (2)
University of Louisville
🇺🇸Louisville, Kentucky, United States
MNGI Digestive Health, P.A.
🇺🇸Coon Rapids, Minnesota, United States
University of Louisville🇺🇸Louisville, Kentucky, United StatesAbigail Stocker, MDContact